Advaxis reports net income of $929,244 for year ended October 31, 2009

Feb 19 2010

Advaxis, Incorporated (OTCBB: ADXS), the live, attenuated Listeria monocytogenes immunotherapy company, today reported results for the fiscal year-ended October 31, 2009.

Net income for the year ended October 31, 2009 totaled $929,244 as compared with a net loss of $5,416,418 for the corresponding period in 2008.

Earnings before interest and taxes (EBIT) for the year ended October 31, 2009 totaled $7,221 as compared with a loss before interest and taxes (LBIT) of $5,416,418 for the corresponding period in 2008.

Cash-on-hand for the year ended October 31, 2009 was $659,822 as compared with $59,738 for the corresponding period in 2008.

Income per share (basic and diluted) for the year ended October 31, 2009 was $0.01 as compared with a loss per share of $0.05 for the corresponding period in 2008.